Hepatitis C Articles (HCV)
Back
	Danoprevir Unboosted activity, safety & resistance       danoprevir displayed potency in this study with 92% in high dose (900mg+PR) achieving cEVR after 12 weeks of treatment   Phase II randomized, partially blind, parallel-group study of oral danoprevir (RG7227) with PegIFN alfa-2a (PEGASYS) plus ribavirin (COPEGUS) in treatment-naive genotype 1 patients with CHC: Results of planned Week 12 interim analysis of the ATLAS study - (11/21/10)           View Older Articles   Back to Top   www.natap.org